Skip to main
ENLV

ENLV Stock Forecast & Price Target

ENLV Analyst Ratings

Based on 2 analyst ratings
Strong Buy
Strong Buy 100%
Buy 0%
Hold 0%
Sell 0%
Strong Sell 0%

Bulls say

Enlivex Therapeutics Ltd demonstrates a strong positive outlook, driven by its advanced clinical results for Allocetra, particularly in a significant patient demographic of those aged 60 and older suffering from idiopathic age-related osteoarthritis, where meaningful reductions in pain and improvements in function were observed. The company’s strategic position with an at-the-market (ATM) facility allows for opportunistic capital raising to bolster liquidity and maintain operational momentum, essential for further development of its immunotherapy pipeline. Additionally, the recent patent application covering Allocetra in osteoarthritis enhances Enlivex's intellectual property position, reinforcing the potential for innovative advancements in a large, unmet musculoskeletal indication.

Bears say

Enlivex Therapeutics is facing uncertainty due to a strategic pivot that requires additional time for evaluation, leading to a cautious approach regarding its stock outlook. The company's reliance on an unconventional capital access strategy, particularly through digital assets, may indicate challenges in generating market recognition for its clinical advancements. Furthermore, while the KOA program's potential milestones could reduce risk, the company's current trajectory raises concerns about its ability to maintain investor confidence and sustain momentum.

ENLV has been analyzed by 2 analysts, with a consensus rating of Strong Buy. 100% of analysts recommend a Strong Buy, 0% recommend Buy, 0% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Enlivex Therapeutics Ltd and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Enlivex Therapeutics Ltd (ENLV) Forecast

Analysts have given ENLV a Strong Buy based on their latest research and market trends.

According to 2 analysts, ENLV has a Strong Buy consensus rating as of Jan 1, 2026. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $10, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $10, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Enlivex Therapeutics Ltd (ENLV)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.